Skip to content

AcuCort as an Investment

Four reasons to invest in AcuCort

    1. Innovative product

      ISICORT®/Zeqmelit addresses a large patient need in acute and severe allergic reactions. The drug is a fast-soluble mouth film that is easy to carry with you and easy to put on the tongue, without the need for water.

    2. Large market

      About 20% of the world’s population suffers from allergic symptoms. The potential market for ISICORT®/Zeqmelit is estimated to be worth more than USD 3 billion.

    3. Low development risk

      The pharmaceutical product is fully developed and approved by the Swedish Medical Products Agency under the brand name ISICORT® and in Denmark and Norway under the name Zeqmelit. Registration processes are ongoing in the rest of the EU.

    4. Competent and experienced team

      Company management and the Board of Directors have broad and deep experience of commercializing new drugs.